- Home
- CAAP vs INDV Comparison
CAAP vs INDV Comparison
Compare CAAP & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAAP | INDV |
|---|---|---|
| Founded | 1998 | N/A |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.4B |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CAAP | INDV |
|---|---|---|
| Price | $25.31 | $40.04 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $26.73 | N/A |
| AVG Volume (30 Days) | 189.8K | ★ 1.7M |
| Earning Date | 05-21-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 8100.00 |
| EPS | N/A | ★ 0.69 |
| Revenue | N/A | ★ $1,239,000,000.00 |
| Revenue This Year | $5.80 | N/A |
| Revenue Next Year | $2.36 | N/A |
| P/E Ratio | ★ $26.35 | $57.67 |
| Revenue Growth | N/A | ★ 4.29 |
| 52 Week Low | $17.36 | $15.00 |
| 52 Week High | $30.50 | $42.81 |
Technical Indicators
Market Signals| Indicator | CAAP | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 44.05 | 56.15 |
| Support Level | $24.94 | $37.64 |
| Resistance Level | $27.17 | $41.00 |
| Average True Range (ATR) | 0.93 | 1.42 |
| MACD | -0.21 | 0.05 |
| Stochastic Oscillator | 12.06 | 41.77 |
Price Performance
Historical ComparisonAbout CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About INDV Indivior PLC
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).